Lv4
796 积分 2022-07-11 加入
Chinese Immune Multi-Omics Atlas
1天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
3天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
3天前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
4天前
已完结
Passenger mutations link cellular origin and transcriptional identity in human lung adenocarcinomas
8天前
已完结
Threshold of adequate resection margin for sub-lobar resection in peripheral clinical stage IA1-2 non-small cell lung cancer with tumor spread through air spaces
10天前
已完结
Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity
16天前
已完结
When ctDNA says ‘maybe’: improving the dynamics of MRD trials
18天前
已完结
Liquid biopsies across the cancer care continuum
18天前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
24天前
已完结
皖公网安备34019202002308
